Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences equity method investment in Galapagos NV / Lakefront Biotherapeutics NV — Fair value carrying amount ($M) ($M)
Form 10-Q / 10-K Note 3 Fair Value & Note 4 Equity Securities
Latest, FY2025
551
Period ended Dec 31, 2025
Change on a year earlier
+19.3%
462 in FY2024
History
7 years
Since FY2018
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Equity method investment in Galapagos NV / Lakefront Biotherapeutics NV — Fair value carrying amount ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 551 | +19.3% | Form 10-Q (gild-20260630.htm, filed 2026-08-06) ↗ |
| FY2024 | Dec 31, 2024 | 462 | – | Form 10-K (gild-20251231.htm, filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 736 | -20.9% | Form 10-Q (gild-20230930.htm, filed 2023-11-07) ↗ |
| FY2021 | Dec 31, 2021 | 931 | -43.5% | Form 10-K (gild-20221231.htm, filed 2023-02-22) ↗ |
| FY2020 | Dec 31, 2020 | 1,648 | -52.6% | Form 10-K (gild-20211231.htm, filed 2022-02-23) ↗ |
| FY2019 | Dec 31, 2019 | 3,477 | +459.0% | Form 10-K (gild-20201231.htm, filed 2021-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 622 | – | Form 10-K (a2019form10-k.htm, filed 2020-02-25) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Equity method investment in Galapagos NV / Lakefront Biotherapeutics NV — Fair value carrying amount ($M) ($M), annual FY2018–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/eq_inv_galapagos
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.